排序方式: 共有93条查询结果,搜索用时 0 毫秒
1.
2.
3.
我们在1979年7~10月对326例受检者血清用免疫酶标测定法进行了EB病毒VCA-IgA抗体滴度测定。其中治疗前鼻咽癌127例,治疗后鼻咽癌20例,非鼻咽癌对照组179例。对治疗前鼻咽癌病人的年龄、性别、临床分期,TNM分期中的原发灶(T)、颈淋巴结转移(N)各期及治疗后鼻咽癌的治愈、复发、转移的EB病毒VCA-IgA抗体的几何平均滴度(GMT)进行统计分析。用非鼻咽癌的健康人、头颈良性及恶性病变患者以及鼻咽粘膜病变患者血清EB病毒VCA-IgA抗体几何平均滴度及阳性率与治疗前鼻咽癌病人进行对比。 相似文献
4.
5.
用改进免疫酶法检测93例治疗前鼻咽癌病人和对照组人群血清的EA/IgA抗体。治疗前病人血清该抗体阳性率为92.4%,平均几何滴度(GMT)1:44.6,而常规法检测阳性率只有75.3%,GMT1:26.9(p<0.01)。对照组中,二种方法检测抗体阳性率无差异。结果表明:改进法测定EA/IgA抗体诊断鼻咽癌更敏感。本文讨论了改进法的优点及重要意义。 相似文献
6.
With gene engineering EB virus membrane antigen as the diagnostic antigen, indirect immunofluo-rescence (IF) assay was used to detect IgA antibody against EB virus membrane antigen (MA-IgA) in sera from 202 nasopharyngeal carcinoma (NPC) patients and 315 controls (normal and patients with other tumors). MA-IgA antibody was positive in 96.8% of the pretreatment NPC patients with a GMT of 1:36.3. MA-IgA detection by this method was more sensitive than EA-IgA detection by IE. In contrast, patients with tumors other than NPC were negative for MA-IgA antibody. 9.1% of VCA-IgA positive persons were MA-IgA positive with a GMT of less than 1:5. No MA-IgA positive was found in VCA-IgA negatives. The results indicated that this method was relatively specific. In the treatment group, the positive rate and GMT of MA-IgA antibody declined with increase in survival time and the decline was faster than VCA-IgA. When recurrence or distant metastasis developed, similar to VCA-IgA and EA-IgA antibodies, the positive rate 相似文献
7.
8.
9.
10.
简史:据文献记载,在公元前3000~3500年前东北非洲和中东人的颅骨标本中,就曾见到有受鼻咽部恶性肿瘤侵犯过的颅骨标本,说明在古代人类就有患鼻咽恶性肿瘤的情况。在欧洲,Durand-Far-del在1837年首次报告鼻咽瘤病例,而Michaux则最早报告病理检查证实的鼻咽癌。在我国,历代医书中都有与鼻咽癌病状相似的论述。如清《医宗金鉴》把瘰疬与失荣,上石疽的诊断就分得很清楚,认为上石疽是“生于颈项旁,坚硬如石,色照常,肝郁凝结于经络,溃石法依瘰疬疮”。失荣的表现是“失荣耳旁及项肩,起如痰核不动坚,皮色如常日渐大,忧思怒郁火凝然,日久气衰形消瘦,越溃越烂现紫班,腐蚀浸淫流血水,疮口翻花治总难”。这种描述与鼻咽癌颈淋巴结转移极相似。直至1921年,在广州首次报告类 相似文献